# EDGAR Filing Document

**Accession Number:** 0001610820
**File Stem:** 0000000000-23-002277
**Filing Date:** 2023-3
**Character Count:** 6529
**Document Hash:** 7de8306d51d469e1c7c738fad2f512e8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-002277.hdr.sgml**: 20230413

**ACCESSION NUMBER**: 0000000000-23-002277

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230308

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BriaCell Therapeutics Corp.
- **CENTRAL INDEX KEY:** 0001610820
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0731

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR
- **CITY:** WEST VANCOUVER
- **STATE:** A1
- **ZIP:** V7T 2X1
- **BUSINESS PHONE:** (604) 921-1810

**MAIL ADDRESS:**
- **STREET 1:** 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR
- **CITY:** WEST VANCOUVER
- **STATE:** A1
- **ZIP:** V7T 2X1

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Ansell Capital Corp.
- **DATE OF NAME CHANGE:** 20140613
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001493152-22-029742

## Text-Extract

```

United States securities and exchange commission logo

                            March 8, 2023

       Gadi Levin
       Chief Financial Officer
       BriaCell Therapeutics Corp.
       Suite 300 - 235 15th Street
       West Vancouver, BC V7T2X1

                                                        Re: BriaCell
Therapeutics Corp.
                                                            Form 10-K for the
Fiscal Year Ended July 31, 2022
                                                            Filed October 28,
2022
                                                            File No. 001-40101

       Dear Gadi Levin:

               We have limited our review of your filing to the financial
statements and related
       disclosures and have the following comment. In our comment, we may ask
you to provide us
       with information so we may better understand your disclosure.

              Please respond to the comment within ten business days by
providing the requested
       information or advise us as soon as possible when you will respond. If
you do not believe our
       comment applies to your facts and circumstances, please tell us why in
your response.

                                                        After reviewing your
response to the comment, we may have additional comments.

       Form 10-K for the Fiscal Year Ended July 31, 2022

       Management's Discussion and Analysis of Financial Condition and Results
of Operations
       Results of Operations
       Research Costs, page 64

   1.                                                   Please disclose the
costs incurred during each period presented for each of your key
                                                        research and
development projects. If you do not track your research and development
                                                        costs by project,
please disclose that fact and explain why you do not maintain and
                                                        evaluate research and
development costs by project. Provide other quantitative or
                                                        qualitative disclosure
that provides more transparency as to the type of research and
                                                        development expenses
incurred (i.e. by nature or type of expense) which should reconcile
                                                        to total research and
development expense on the Statements of Operations.

              In closing, we remind you that the company and its management are
responsible for the
       accuracy and adequacy of their disclosures, notwithstanding any review,
comments, action or
 Gadi Levin
BriaCell Therapeutics Corp.
March 8, 2023
Page 2

absence of action by the staff.

      You may contact Christine Torney at (202) 551-3652 or Vanessa Robertson
at (202) 551-
3649 with any questions.

FirstName LastNameGadi Levin                            Sincerely,
Comapany NameBriaCell Therapeutics Corp.
                                                        Division of Corporation
Finance
March 8, 2023 Page 2                                    Office of Life Sciences
FirstName LastName

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

CORPORATION FINANCE

# UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

March 8, 2023

Gadi Levin  
Chief Financial Officer  
BriaCell Therapeutics Corp.  
Suite 300 - 235 15th Street  
West Vancouver, BC V7T2X1

**Re: BriaCell Therapeutics Corp.  
Form 10-K for the Fiscal Year Ended July 31, 2022  
Filed October 28, 2022  
File No. 001-40101**

Dear Gadi Levin:

We have limited our review of your filing to the financial statements and related disclosures and have the following comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to the comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response.

After reviewing your response to the comment, we may have additional comments.

Form 10-K for the Fiscal Year Ended July 31, 2022

Management's Discussion and Analysis of Financial Condition and Results of Operations

1. Please disclose the costs incurred during each period presented for each of your key research and development projects. If you do not track your research and development costs by project, please disclose that fact and explain why you do not maintain and evaluate research and development costs by project. Provide other quantitative or qualitative disclosure that provides more transparency as to the type of research and development expenses incurred (i.e. by nature or type of expense) which should reconcile to total research and development expense on the Statements of Operations.

In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or

Gadi Levin
BriaCell Therapeutics Corp.
March 8, 2023
Page 2

absence of action by the staff.

You may contact Christine Torney at (202) 551-3652 or Vanessa Robertson at (202) 551-3649 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences